Ovid Therapeutics (OVID) EPS (Weighted Average and Diluted) (2020 - 2026)
Ovid Therapeutics (OVID) reported EPS (Weighted Average and Diluted) of -$0.12 for Q1 2026, up 99.91% on a YoY basis from -$0.06 in Q1 2025, and down 100.03% quarter-over-quarter from $374.07 in Q4 2025.
Ovid Therapeutics (OVID) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Ovid Therapeutics has reported EPS (Weighted Average and Diluted) for 7 years, with the latest figure at -$0.12 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 99.91% year-over-year to -$0.12; the trailing twelve-month figure through Mar 2026 stood at $206.0 (up 152.79% YoY), and the FY2025 full-year result was -$0.23, up 99.94% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.12, down from $374.07 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $374.07 in Q4 2025, with the low at -$366.09 in Q4 2024.
- Historically, EPS (Weighted Average and Diluted) has averaged -$10.94 across 5 years, with a median of -$0.18 in 2023.
- The largest YoY upside for EPS (Weighted Average and Diluted) was 65438.89% in 2024 against a maximum downside of 174228.57% in 2024.
- Ovid Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.16 in 2022, then sank by 31.25% to -$0.21 in 2023, then tumbled by 174228.57% to -$366.09 in 2024, then jumped by 202.18% to $374.07 in 2025, then sank by 100.03% to -$0.12 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.12 (Q1 2026), $374.07 (Q4 2025), and -$168.01 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Ovid Therapeutics | 311.83 Mn | 156.31 Mn | - | -0.12 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.12 |
| Dec 31, 2025 | 374.07 |
| Sep 30, 2025 | -168.01 |
| Jun 30, 2025 | -0.06 |
| Mar 31, 2025 | -141.57 |
| Dec 31, 2024 | -366.09 |
| Sep 30, 2024 | -0.20 |
| Jun 30, 2024 | 117.61 |
| Mar 31, 2024 | -0.17 |
| Dec 31, 2023 | -0.21 |
| Sep 30, 2023 | -0.16 |
| Jun 30, 2023 | -0.18 |
| Mar 31, 2023 | -0.19 |
| Dec 31, 2022 | -0.16 |
| Sep 30, 2022 | -0.17 |
| Jun 30, 2022 | -0.21 |
| Mar 31, 2022 | -0.23 |
| Dec 31, 2021 | -0.38 |
| Sep 30, 2021 | -0.17 |
| Jun 30, 2021 | -0.23 |